You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 4, 2024

Claims for Patent: 9,744,207

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,744,207

Title:	Pharmaceutical compositions with enhanced stability
Abstract:	The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a beneficial salt of a luteinizing hormone releasing hormone (LHRH) analog formed with a strong acid that minimizes or prevents the interaction/reaction between the LHRH and the polymer in an organic solution; b) a biodegradable polymer; c) a pharmaceutically acceptable organic solvent; and d) optionally one or more excipients. The present invention also relates to a method of manufacturing and a method of use thereof.
Inventor(s):	Li; Yuhua (Landenberg, PA), Chien; Benjamin (Woodside, CA)
Assignee:	Foresee Pharmaceuticals Co., Ltd. (Taipei, TW)
Application Number:	15/406,321
Patent Claims:	1. An injectable polymeric composition comprising: a) a salt of a luteinizing hormone releasing hormone (LHRH) analogue formed with a strong acid selected from the group consisting of methanesulfonic acid, hydrochloric acid, and sulfuric acid; b) a biodegradable polymer selected from the group of polylactide, poly(lactic acid), poly(lactic acid-co-glycolic acid), and poly(lactide-co-glycolide); and c) a pharmaceutically acceptable organic solvent, wherein the composition does not contain excess of the strong acid in addition to the strong acid used to form the salt. 2. The injectable polymeric composition of claim 1, wherein the pharmaceutically acceptable organic solvent is selected from a group of N-methyl-2-pyrrolidone (NMP) and Dimethyl sulfoxide (DMSO). 3. The injectable polymeric composition of claim 1, wherein the LHRH analogue is LHRH agonist selected from the group consisting of leuprorelin, buserelin, gonadorelin, deslorelin, fertirelin, histrelin, lutrelin, goserelin, nafarelin, triptorelin, enfuvirtide, and thymosin .alpha.1. 4. The injectable polymeric composition of claim 1, wherein the LHRH analogue is LHRH antagonist selected from the group consisting of cetrorelix and abarelix. 5. The injectable polymeric composition of claim 1, wherein the biodegradable polymer has a weight average molecular weight of between about 2,000 to about 100,000 dalton. 6. The injectable polymeric composition of claim 1, wherein the biodegradable polymer is manufactured with a dodecanol (or lauryl alcohol) as an initiator resulting in a polymer with one hydroxyl end group at one end and one dodecyl ester group at the other end. 7. The injectable polymeric composition of claim 1, wherein the biodegradable polymer is manufactured with a 1,6-hexanediol as an initiator resulting in a polymer with one hydroxyl group at both ends of the polymer. 8. The injectable polymeric composition of claim 1 comprising: a) 0.01-40% w/w a salt of a luteinizing hormone releasing hormone (LHRH) analogue formed with a strong acid selected from the group consisting of methanesulfonic acid, hydrochloric acid, and sulfuric acid; b) 40-60% w/w the biodegradable polymer selected from the group consisting of polylactide and poly(lactic acid); and c) 30-80% w/w N-methyl-2-pyrrolidone, wherein the composition does not contain excess of the strong acid in addition to the strong acid used to form the salt. 9. The injectable polymeric composition of claim 5, wherein the biodegradable polymer has an average molecular weight of about 8,000 to about 50,000. 10. An injectable polymeric composition of claim 1 comprising: a) 0.01-40% w/w a salt of a luteinizing hormone releasing hormone (LHRH) analogue formed with a strong acid selected from the group consisting of methanesulfonic acid, hydrochloric acid, and sulfuric acid; b) 30-60% w/w biodegradable polymer selected from the group consisting of poly(lactide-co-glycolide) and poly(lactic acid-co-glycolic acid), having the ratio of lactide:glycolide or lactic acid:glycolic acid of from 50:50 to about 100:0; and c) 30-80% w/w N-methyl-2-pyrrolidone, wherein the composition does not contain excess of the strong acid in addition to the strong acid used to form the salt. 11. The injectable polymeric composition of claim 7, wherein the poly(lactide-co-glycolide) or poly(lactic acid-co-glycolic acid) has a ratio of lactide:glycolide or lactic acid:glycolic acid of about 85:15. 12. The injectable polymeric composition of claim 7, wherein the poly(lactide-co-glycolide) or poly(lactic acid-co-glycolic acid) has an average molecular weight of about 15,000 to about 50,000.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.